Does Topamax Affect Sex Drive? What the Topiramate Studies Actually Show

Topamax and sex drive has no placebo-controlled answer anywhere in the record. Topamax (topiramate) has never been counted for sexual side effects in a trial with a placebo arm. The one systematic review, covering 17 publications, put self-reported sexual problems at 9.0% in polytherapy observational studies. Desire problems came in at the same 9.0%, finishing problems at 2.6%, on grade C evidence. The case series point one way, and that direction is dose-related and reversible: in 7 people taking 45 to 200 milligrams a day for migraine, six recovered within 7 days of stopping or lowering the dose.

Figures from Chen et al. 2017 (PMID 28605628), Sun et al. 2006 (PMID 17040342) and Adelman et al. 2008 (PMID 18298700). The first reviews observational reports, the second is a case series, the third a pooled safety analysis with no sexual endpoint.

Is it the Topamax, or is it me?

You typed this into a search bar because something changed and you want a name for it. Start by admitting the tangle. Migraine flattens desire on its own: the attacks, the dread of the next one, the broken sleep around them. Epilepsy carries its own load, from seizures to driving rules to the fear of one happening in front of someone. Weight brings its own noise, a scale and a room full of comments. Topiramate often arrives for all of this at once, so your question reaches the neurologist tangled.

This page sorts what exists by size. One systematic review counted self-reported sexual problems, and that is the only counted figure in the whole set. Case reports describe individual people in careful detail, and a description carries no rate. The large safety pools cover thousands of people and never asked about sex, so their silence settles nothing in either direction.

Situations sitting next to yours have evidence of their own, and it is worth reading the page for the one you are actually in: gabapentin and sex drive, lamotrigine and sex drive, chronic pain and low sex drive.

The one counted figure, and where it comes from

Chen and colleagues (2017) ran the only systematic review on this question, following PRISMA guidelines, and reviewed 17 publications of sexual problems reported during topiramate use. Every number in it comes from limited polytherapy observational studies, meaning people taking several antiseizure drugs at once. Self-reported topiramate-associated sexual problems came out at 9.0%. Desire problems came out at the same 9.0%. Finishing problems came out at 2.6%. That is grade C evidence, the weak end of the grading scale, with no placebo arm behind any bar.

The pattern inside those percentages is consistent. Women mainly reported trouble finishing. Men mainly reported erection problems. The daily dose in the people who reported sexual problems sat within the recommended dose range, so this was not a megadose finding. Sexual adverse effects usually appeared from 4 weeks after starting topiramate, and in every person they subsided without eventful complications once topiramate was substituted or the dose reduced.

The abstract never gives a denominator. The number of people behind the 9.0% is not printed, nor are the study designs inside the 17 publications, the follow-up length, the name of any questionnaire. Read 9.0% as a rate reported by a small, selected group of people who answered in their own words.

Yang and Wang (2016) reviewed sexual problems related to antiseizure drugs and list topiramate, pregabalin, gabapentin among the newer drugs reported to cause them. Oxcarbazepine, lamotrigine, levetiracetam are listed as drugs reported to improve function. It is a narrative review resting on expert opinion, with no pooling and no count attached to topiramate.

The large datasets never asked. Shorvon (1996) reported 1,809 people exposed to topiramate, 665 treated for more than a year, 177 for more than 3 years, with nervous-system effects appearing more often above the 200 to 600 milligram a day range and kidney stones not requiring surgery in 1.5%. No sexual count appears. Donegan and colleagues (2015) pooled 90 randomized placebo-controlled trials across indications, and six events differed from placebo in both directions, every one of them nervous system: ataxia, disturbance in attention, dizziness, memory impairment, paraesthesia, somnolence.

One more point belongs with this figure. Difficulty with concentration is a counted effect of topiramate, and it reaches desire through attention and through sleep. Our page on brain fog and sex drive covers that route.

What the case reports describe

Sun and colleagues (2006) published the series that made this effect visible. Seven people, 5 women, 2 men, aged 40 to 62. Four women and two men had migraine without aura, one woman had migraine with aura. None had a prior history of trouble finishing or any sexual problem. They took topiramate for migraine prevention at doses from 45 to 200 milligrams daily, and they lost the ability to finish.

All seven got it back. Six recovered within 7 days of discontinuing or decreasing the medication, and the exact time frame for the seventh person is not known. The authors read the pattern as reversible and dose related, and they say prescribers should ask about these effects directly, because nobody volunteers them.

Calabrò and colleagues (2009) describe one man with epilepsy who developed reversible erection problems on topiramate. The authors ran psychological testing. They added neurophysiological testing, ultrasound, laboratory work. Other explanations were excluded, and the case is presented as drug related. Civardi and colleagues (2012) describe two men with epilepsy who developed erection problems during topiramate use. Their hormone panel did not move, so the authors argue that a blood-vessel mechanism has to be considered, an inference drawn from two people.

Wu and colleagues (2016) report a 39-year-old man with partial epilepsy on 100 milligrams a day. Eleven days after starting he began involuntary semen loss every 2 to 3 days, with loss of desire, lack of energy, poor appetite, frequent urination, night-time urination. It ran for 2 months. After topiramate was withdrawn the problems disappeared and did not come back.

A case report describes one person. Seven people who improved, one man whose tests were worked through, one man with night-time urination: that is detail, and detail carries no denominator. None of these papers knows how many people were treated in total, so none of them can tell you how common this is.

If wanting is the part that changed for you, and finishing is fine, start with our guide to low libido in men.

Hormones: what was measured

The fear under this search is that topiramate has knocked your testosterone around. The measurements that exist are few, and they point away from that story.

Civardi and colleagues (2012) measured serum sexual hormones in two men with epilepsy during topiramate use and at several time intervals after stopping. Total testosterone, free testosterone, bioavailable testosterone, sex hormone-binding globulin: none of it was affected. The erection problems could not be tied to hormone changes, so the authors propose a blood-vessel mechanism, and nothing was measured to support that proposal.

Jacobsen and colleagues (2008) looked for a hormone route in a laboratory, testing 12 antiseizure drugs on aromatase (CYP19) in microsomes from transfected insect cells. Seven drugs inhibited the enzyme, with 50% reduction in activity in the range of 1.4 to 49.7 mM: lamotrigine, oxcarbazepine, tiagabine, phenobarbital, phenytoin, ethosuximide, valproate. Carbamazepine, gabapentin, primidone, topiramate, vigabatrin showed no inhibition. Valproate plus phenobarbital produced additive inhibition, and adding carbamazepine to a range of valproate concentrations gave no extra inhibition. No person was measured, and no blood hormone level was read.

Where the data is missing, say so. Ortiz Salas and colleagues (2022) systematically reviewed polycystic ovary syndrome in women of reproductive age taking antiseizure drugs, screened 2043 references, and found four articles meeting the inclusion criteria, covering oxcarbazepine, lamotrigine only. No article described topiramate at all, and the authors state that the risk cannot be established for lack of studies. Fuentes-Mendoza and colleagues (2026), reviewing sexual function and weight-loss medications, describe phentermine/topiramate as primarily enhancing psychological well-being, with sexual endpoints typically secondary in trials and the evidence inconsistent.

If you want the hormone question settled before you spend money on it, read do testosterone boosters work. If the number on the scale moved and your drive did not, weight loss and libido is the closer page.

The side effects that were counted

Adelman and colleagues (2008) pooled safety data from controlled migraine prevention trials: 1,580 people across three randomized, double-blind, placebo-controlled registration trials plus an earlier pilot randomized, double-blind, placebo-controlled trial. The safety population took at least one dose in the double-blind phase: 235 people on 50 milligrams a day, 386 on 100 milligrams, 514 on 200 milligrams, 445 on placebo.

Paresthesia, pins and needles in the fingers, toes, around the mouth, was the most common reported effect: 35% at 50 milligrams a day, 51% at 100 milligrams, 49% at 200 milligrams, against 6% on placebo. Effects were mostly mild or moderate and appeared at higher rates during titration than maintenance. Effects leading to withdrawal at the recommended target dose of 100 milligrams a day (50 milligrams twice daily) ran: paresthesia 8%, fatigue 5%, nausea 2%, difficulty with concentration 2%. Serious effects occurred in 2% of 1,135 topiramate-treated people and 3% of 445 placebo-treated people. Mean body weight fell against placebo.

Luykx and colleagues (2009) compared published monotherapy trials in epilepsy against migraine: four epilepsy trials with 1,179 people against active comparators, six migraine trials with 1,723 people against placebo. Risk ratios for paresthesia in migraine against epilepsy trials were 2.5 (99% CI 1.66 to 3.77) at 50 milligrams, 2.7 (99% CI 1.80 to 3.97) at 100 milligrams, 3.0 (99% CI 1.95 to 4.56) at 200 milligrams. For adverse-reaction-related dropouts the risk ratio was 2.5 (95% CI 2.03 to 2.98) at 50 milligrams, with no difference at the other doses. Those two groups were never randomized against each other.

The counted list also carries Donegan and colleagues (2015), where six events differed from placebo in both directions: ataxia, disturbance in attention, dizziness, memory impairment, paraesthesia, somnolence. Shorvon (1996) adds nervous-system effects more often above the 200 to 600 milligram a day range, kidney stones in 1.5%, mild dose-related weight loss. Shamabadi (2022) pooled nine randomized trials in depression covering 784 people and found topiramate effective and tolerable as monotherapy and as add-on therapy, with tolerability left undefined.

No sexual endpoint sits in any of that. What was counted is fatigue, difficulty with concentration, sleepiness, memory problems. Each of those flattens desire on other pages of ours, which is how a drug with no sexual count can still cost you your drive. See depression and low libido and sleep, libido and testosterone.

What has been counted, in order

Seven published looks at Topamax (topiramate) and sex, in the order they appeared, make up the whole record. Two of them counted anything to do with desire. The rest counted nerve effects, weight, a hormone enzyme in a test tube, or one person at a time. That shape matters more than any single number on this page. A drug used by a very large number of people for migraine, epilepsy and weight loss carries one systematic review on this question, and that review grades its own evidence C. Below they are in order, then a table of what each study measured and what that measurement can tell you about wanting sex.

Topamax in the studies: what each measured, and what it says about desire

Study	Design	Who	Finding	What it says about desire
Chen 2017	Systematic review	17 publications	9.0% sexual problems, 9.0% desire problems, 2.6% finishing problems	The only count in the set. Grade C, polytherapy, self-report, no placebo arm
Sun 2006	Case series	7 people, aged 40 to 62	45 to 200 milligrams daily, reversible within 7 days in six of seven	A description of seven people. A description carries no rate
Wu 2016	Case report	One man, 39 years old	Desire lost from day 11 on 100 milligrams a day, gone after withdrawal	One person. It says the effect happened, never how often
Civardi 2012	Case series	Two men with epilepsy	Erection problems, testosterone and sex hormone-binding globulin unchanged	A mechanism the authors inferred from two people. No desire measure
Adelman 2008	Pooled trial safety	1,580 people, migraine trials	Paresthesia 35%, 51% and 49% by dose against 6% on placebo	Nothing. No sexual endpoint was measured in any of these trials
Luykx 2009	Meta-analytic comparison	1,179 and 1,723 people	Paresthesia risk ratios 2.5 (99% CI 1.66 to 3.77), 2.7 (1.80 to 3.97), 3.0 (1.95 to 4.56) in migraine against epilepsy trials	Nothing. No sexual outcome, and the groups came from separate trials with different comparators
Donegan 2015	Systematic review	90 placebo-controlled trials	Six nervous-system events differ from placebo, including paraesthesia and somnolence	Nothing. Every counted event is nervous system related
Jacobsen 2008	Test tube	12 drugs, insect-cell microsomes	Topiramate showed no aromatase inhibition	Nothing in people. It clears one hormone mechanism in a lab dish

What actually helps, graded honestly

The only counted good news in this record is reversibility, and every step of it belongs to your prescriber. In Chen and colleagues (2017), the sexual adverse effects subsided without eventful complications after topiramate substitution or dose reduction in all people. In Sun and colleagues (2006), six of seven people recovered within 7 days of stopping or lowering the medication, and the time frame for the seventh is unknown. In Wu and colleagues (2016), everything disappeared after withdrawal and stayed away. Three reports point the same way, and none of them is a trial.

The dose line runs through all three. Sun's cases sat between 45 and 200 milligrams daily. Shorvon (1996) found nervous-system effects more often above the 200 to 600 milligrams a day range that dose ranging trials called optimal. Adelman and colleagues (2008) set the recommended target at 100 milligrams a day. A lower dose is a conversation with the doctor who prescribed it, and nothing written on this page changes that.

Then there is asking. Chen's figures are self-reported, which means somebody in those studies asked the question. Sun's authors close by saying prescribers should ask about these effects. Most people never bring it up, and most short visits never get there. The guide to low libido in women covers how to open the subject, and why is my libido so low walks the longer list of causes.

The counted effects can also flatten wanting on their own. At 100 milligrams a day, Adelman's pool lists withdrawal for fatigue in 5% and for difficulty with concentration in 2%. Donegan and colleagues (2015) pooled 90 placebo-controlled trials and found memory impairment and somnolence differ from placebo. Being tired all the time and losing your train of thought are their own problem, and brain fog and sex drive covers that pair. Nobody in any of these studies tested any of it against desire.

Does it wear off on its own?

Everyone wants to know whether it settles out. The record has no answer for staying put. Chen and colleagues (2017) put onset usually from 4 weeks after starting, and every case subsided after the drug was substituted or the dose came down; nothing there follows people who stayed on the same dose and waited. Sun and colleagues (2006) recorded resolution within 7 days of stopping or lowering the medication. Adelman and colleagues (2008) found the counted effects ran at higher rates during titration than during maintenance, the closest thing to a settling signal in the whole set. Wu and colleagues (2016) described a man whose effects ran for 2 months on the drug and disappeared after withdrawal. Waiting it out is one of the options nobody studied.

What to bring to your doctor

Six things make this appointment short. Write them down first, bring the bottle, and read the list out loud if you have to. Nobody measured your desire on a questionnaire, so the numbers here are yours to supply, in your own words.

1. Your dose and your titration dates. Sun's cases sat between 45 and 200 milligrams daily, and Adelman's pool shows effects running higher during titration than maintenance.
2. What changed, in plain words: desire, trouble finishing, erection problems. Chen's review found women mainly had trouble finishing and men mainly had erection problems, so name the one you have.
3. When it started. Chen puts onset usually from 4 weeks after starting, and the man in Wu's report began on day 11. A date is more useful to a neurologist than a feeling.
4. The fatigue and concentration picture. At 100 milligrams a day, Adelman lists withdrawal for fatigue in 5% and difficulty with concentration in 2%, and Donegan counted memory impairment and somnolence against placebo.
5. How the migraine or seizure control itself is going, since substitution and dose reduction are the two moves that closed every case in Chen's review.
6. The supplement question, bottle in hand, including anything botanical and anything you take for sleep.

The everyday levers, and where a botanical fits

Start with who this section is not for. Kidney, heart and lung problems are common, blood-pressure medication is common, and they are exactly what NUUD's own label warns about: "avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients". For some readers that sentence is the whole answer. Talk to your doctor first, and bring the bottle to that conversation.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits. Two of them matter more than usual on a drug whose counted effects include fatigue and sleepiness.

• Sleep, in amount and in quality, since a drug that causes somnolence and a headache that wakes you both take money out of the same account. Sleep, libido and testosterone covers how little it takes to move the needle.
• Movement you can keep up, built around the hours when you have energy. Exercise and libido covers the wider picture.
• Your mood and your anxiety, said out loud at an appointment and taken as seriously as the headache diary.
• Time with a partner where nothing is expected at the end, planned for a day the headache is quiet.
• A botanical supplement, if you want one, as the smallest lever on this list.

NUUD is a botanical supplement built around desire in general. It does nothing for Topamax (topiramate), for topiramate's side effects, for migraine, for seizures, or for weight, and no interaction study exists for this formula and topiramate. It has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your doctor decides the rest. If your doctor has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Two unhelpful answers are waiting for you, and you have probably heard both. The first is the shrug: everything gives somebody trouble, it is printed on the list, live with it. The record here is thin, and it is not a shrug. Chen's review counted desire problems in 9.0% of people in observational studies of polytherapy, evidence graded C, and every one of those cases settled when the drug changed. Thin data is still a number, and reversibility is worth something.

The second answer is the forum certainty that Topamax flattens libido in everyone and you are finished. That is not in the record either. Sun's series covers seven people. Wu's covers one. The 9.0% comes from self-report in weak data with no placebo comparison. What is solid is that paresthesia showed up in 51% of people at 100 milligrams a day against 6% on placebo, in a pool of 1,580 where nobody counted desire.

Migraine flattens wanting. Being tired all the time flattens wanting. A drug that works can flatten wanting at the same time it stops the headache. Wanting both is reasonable. I just want to feel normal again is the sentence people bring to the appointment, and it is the right one to say out loud.

Keep reading

• Does gabapentin affect sex drive?
• Does lamotrigine affect sex drive?
• Chronic pain and low sex drive
• Brain fog and sex drive
• Why weight loss did not fix low libido
• Why is my libido so low?

Frequently asked questions

Does Topamax lower sex drive?
It can, and the count is thin. No placebo-controlled trial measured desire on Topamax (topiramate). Chen and colleagues (2017) reviewed 17 publications and found self-reported desire problems in 9.0% of people on polytherapy, evidence graded C, meaning limited observational studies with no placebo comparison. Wu and colleagues (2016) documented one man who lost desire on 100 milligrams a day. Adelman and colleagues (2008) counted fatigue and difficulty with concentration in 1,580 people and never measured desire at all.

How common are Topamax sexual side effects?
One number exists. Chen and colleagues (2017) reported self-reported topiramate-associated sexual problems in 9.0%, desire problems in 9.0% and finishing problems in 2.6%, all from limited observational studies of people on polytherapy, graded C evidence. Nothing else is counted. Adelman and colleagues (2008) pooled 1,580 people in migraine trials and measured no sexual endpoint. Donegan and colleagues (2015) reviewed 90 placebo-controlled trials across every indication and found differences only in nervous-system events. Treat 9.0% as a starting point for a conversation.

Does Topamax cause erection problems?
Erection problems are reported, with no rate attached. Chen and colleagues (2017) found that men in the reviewed studies mainly had erection problems. Calabro and colleagues (2009) described one man whose erection problems appeared on topiramate, with psychological, neurophysiological, ultrasound and laboratory testing used to exclude other explanations. Civardi and colleagues (2012) described two men whose testosterone and sex hormone-binding globulin levels stayed unchanged. Three published accounts describe a pattern in a few people, and none of them can tell you how often it happens.

Do Topamax sexual side effects go away?
In every published account here, they did. Chen and colleagues (2017) reported that sexual adverse effects subsided without eventful complications after topiramate substitution or dose reduction in all people. Sun and colleagues (2006) recorded six of seven people recovering within 7 days of stopping or lowering the medication, with the seventh time frame unknown. Wu and colleagues (2016) described effects that disappeared after withdrawal and did not return. Substitution and dose reduction are decisions your prescriber makes, and stopping an antiseizure drug on your own carries its own risk.

Can I take a botanical supplement with Topamax?
Ask your prescriber first, with the bottle in hand. The label caution is the filter: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. NUUD is a botanical supplement and does nothing for Topamax (topiramate), for migraine, or for seizures. No interaction studies exist for this formula and topiramate, so the answer has to come from the person who knows your full list.

References

1. Calabrò RS, Bramanti P, Italiano D, Ferlazzo E. Topiramate-induced erectile dysfunction. Epilepsy & behavior : E&B. 2009;14(3):560-1. https://pubmed.ncbi.nlm.nih.gov/19189861/
2. Chen LW, Chen MY, Chen KY, Lin HS, Chien CC, Yin HL. Topiramate-associated sexual dysfunction: A systematic review. Epilepsy & behavior : E&B. 2017;73:10-17. https://pubmed.ncbi.nlm.nih.gov/28605628/
3. Yang Y, Wang X. Sexual dysfunction related to antiepileptic drugs in patients with epilepsy. Expert opinion on drug safety. 2016;15(1):31-42. https://pubmed.ncbi.nlm.nih.gov/26559937/
4. Civardi C, Collini A, Gontero P, Monaco F. Vasogenic erectile dysfunction Topiramate-induced. Clinical neurology and neurosurgery. 2012;114(1):70-1. https://pubmed.ncbi.nlm.nih.gov/21868149/
5. Ortiz Salas PA, Rodríguez JH, Florez SJB, Suarez FE. Polycystic ovary syndrome and the new antiepileptic drugs: A systematic review. Epilepsy research. 2022;185:106968. https://pubmed.ncbi.nlm.nih.gov/35843017/
6. Donegan S, Dixon P, Hemming K, Tudur-Smith C, Marson A. A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug?. Epilepsia. 2015;56(12):1910-20. https://pubmed.ncbi.nlm.nih.gov/26662191/
7. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain medicine (Malden, Mass.). 2008;9(2):175-85. https://pubmed.ncbi.nlm.nih.gov/18298700/
8. Jacobsen NW, Halling-Sørensen B, Birkved FK. Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicology in vitro : an international journal published in association with BIBRA. 2008;22(1):146-53. https://pubmed.ncbi.nlm.nih.gov/17959350/
9. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache. 2006;46(9):1450-3. https://pubmed.ncbi.nlm.nih.gov/17040342/
10. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clinical pharmacology and therapeutics. 2009;85(3):283-8. https://pubmed.ncbi.nlm.nih.gov/18987621/
11. Wu M, Hao N, Zhou D. Spermatorrhea and Loss of Libido Induced by Topiramate: First Case Report and Review of Literature. Clinical neuropharmacology. 2016;39(6):325-326. https://pubmed.ncbi.nlm.nih.gov/27755132/
12. Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Mendoza-Godoy JJ, Concepción-Urteaga L, Paz-Ibarra J, Coronado-Arroyo JC. Beyond metabolism: sexual dysfunction and weight-loss drugs. Sexual medicine reviews. 2026;14(1):. https://pubmed.ncbi.nlm.nih.gov/41427954/
13. Shamabadi A. Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials. Neuropsychopharmacology reports. 2022;42(4):421-429. https://pubmed.ncbi.nlm.nih.gov/35912516/
14. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37 Suppl 2:S18-S22. https://pubmed.ncbi.nlm.nih.gov/8641242/

This article is for general education and is not medical advice. Migraine, epilepsy and obesity are medical conditions that only a licensed clinician can diagnose and manage. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing any of them or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change any medication without your doctor.